| Management target | Revenue 100.0% FY27 |
|---|
| Revenue growth | 38% YoY revenue growth to 72.97 Cr in Q1 FY27. |
|---|---|
| Margins | EBITDA margin improved to 29%; 35%+ targeted via API integration. |
| Demand visibility | Strong, backed by 65+ contracts and 50+ international opportunities. |
| Management confidence | High, focused on scaling specialized oncology exports and API integration. |
Growth
Oncology grew 100%+, contributing 33 Cr. Export contribution remains low but is expected to scale 10x.
Outlook
Guided to double Oncology revenue this FY; aiming for 280-300 Cr Oncology revenue by FY28.
Risks
Low export contribution currently and reliance on long timeline marketing authorization approvals for growth.
Last quarter's promises, checked
Delivered
- Guided 40% growth for FY26 → delivered 42% (= BEAT)
- Guided 60% gross margins → delivered 60% (= BEAT)
- Guided 25-30% EBITDA margins → delivered 37% in Q4 (= BEAT)
Partly delivered
- Guided 300+ dossier registrations in 2 years → 130+ filed, 12 approved (= PARTIAL)
Missed
- Guided Q4 run rate near 38-40 Cr oncology → delivered 31.46 Cr (= MISS)
Earnings Call Transcript filed with NSE, NSE: SAKAR. Summary written with AI assistance from the document.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹1,028.80
- Market cap
- ₹2,289 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 63.4×Sector 47.4×
- Promoter holding
- 52.52%-0.34% QoQ
- FII holding
- 12.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Other Announcement
Sakar Healthcare Limited appointed M/s. Kashyap R. Mehta & Partners as the company's Secretarial Auditors for a five-year term, effective September 22, 2026, following shareholder approval at the AGM.
Sakar Healthcare Annual General Meeting
Sakar Healthcare's 22nd AGM was held on September 22, 2026, adopting audited financials and re-appointing a director. Routine resolutions were passed including secretarial auditor appointment.
Sakar Healthcare Regulatory Approval
Sakar Healthcare Limited received 14 oncology product approvals in the EU, UK, and Canada. These approvals for licensed-out products and site variations will drive top-line sales growth.
Sakar Healthcare Annual General Meeting
Sakar Healthcare Limited submitted its 22nd Annual General Meeting notice and the Annual Report for FY 2025-26. The meeting is scheduled for September 22, 2026.
Sakar Healthcare Investor Presentation: Key Takeaways
Sakar Healthcare reported strong Q1FY27 consolidated results with 38% Revenue growth and 120% PAT growth, driven by its vertically integrated oncology business and expansion into regulated markets.
Sakar Healthcare Results Update
Sakar Healthcare announced Q1FY27 results, reporting 38% YoY revenue growth. Strong operating performance was driven by oncology product contracts and global dossier approvals.